A recent study reveals comparable outcomes for radical cystectomy and bladder-sparing therapy in treating recurrent ...

While the current approval focuses on the second-line setting, research is already moving into earlier stages of the ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that adult patients ...

Padcev is approved for use in combination with the programmed death 1 inhibitor Keytruda (pembrolizumab) or Keytruda QLEX (pembrolizumab and berahyaluronidase alfa-pmph) as neoadjuvant treatment and ...

Nearly 20,000 women are diagnosed with bladder cancer each year, according to the American Cancer Society, with most being over age 55. And the unfortunate reality is that women are often diagnosed at ...

“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility,” by Astellas Pharma Inc. News release; Dec. 17, 2025.

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...

Non muscle invasive bladder cancer means the cancer cells are only in the bladder’s inner lining. It’s also called superficial bladder cancer. This page is about treatment options for non muscle ...

Bladder cancer patients given an immunotherapy drug are a third less likely to see disease come back and are more likely to survive, according to a 'game-changer' study. Patients with advanced (muscle ...

Protect your bladder health with these 5 essential health checks. Learn which tests and screenings you need to maintain ...